Can you provide more details on the pharmacy and telehealth partnerships? How do these partnerships align with the company's long-term strategic goals?
How many practitioners are registered to prescribe Spontan under the special access scheme, and how many are actively prescribing.
What is the re prescription/ re purchase rate? How many patients are coming back and re purchasing the product?
Are the prescriber's only associated with restorative health or are there general practitioners around Australia prescribing in a GP setting?
What specific strategies are being implemented to sustain and accelerate prescriber growth in Australia?
Have we seen any adverse effects under the SAS that were not found in the initial study?
What are the financial projections for the next fiscal year, and how does the board plan to ensure the company remains financially robust during the product development and market expansion phases?
When do you anticipate the next capital raise?
LTP Price at posting:
43.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)